Apiphos Sachet – Fosfomycin Trometamol 3 gm

Apiphos Sachet delivers Fosfomycin Trometamol 3 gm — a novel class of phosphonic antibiotic that stands apart from every conventional UTI treatment in one critical way: it works in a single dose. As the only antimicrobial approved by the FDA for single-dose therapy in women with acute cystitis, Apiphos eliminates the compliance challenges of multi-day antibiotic courses while delivering potent, sustained bactericidal action.

In a healthcare landscape where multi-drug resistant UTIs are increasing and antibiotic compliance is a constant challenge, Apiphos offers clinicians a scientifically validated, patient-friendly solution that is as effective as 7-day antibiotic regimens — in a single convenient sachet.

What Makes Fosfomycin Unique

Fosfomycin Trometamol belongs to the phosphonic acid class of antibiotics — a chemically distinct category with a unique mechanism of action that differs entirely from penicillins, cephalosporins, fluoroquinolones, and nitrofurantoin. This distinct mechanism means:

• No cross-resistance with existing antibiotic classes
• Effective against Multi-Drug Resistant Organisms (MDRO) including strains resistant to fluoroquinolones and trimethoprim
• Clinically proven efficacy against the most common UTI pathogens

Pharmacokinetic Advantage — The Single Dose Science

• A single 3 gm dose produces peak urinary concentrations within 4 hours
• Urinary concentrations remain high (greater than 128 mcg/ml) for 24–48 hours — sufficient to inhibit most urinary tract pathogens
• A single dose is as clinically effective as a 7-day course of nitrofurantoin, norfloxacin, or trimethoprim/sulphamethoxazole
• Rapid oral absorption with excellent urinary penetration

Spectrum of Activity

Apiphos demonstrates broad-spectrum bactericidal activity against the organisms most commonly responsible for UTIs:

• More than 90% of E. coli and Citrobacter spp. were susceptible to Fosfomycin in clinical studies
• Effective against Klebsiella, Enterobacter, Proteus mirabilis, Staphylococcus, and Enterococcus species
• Active against MDRO strains — including those resistant to quinolones and other first-line agents

Clinical Indications

For Treatment of Bladder Infection (Cystitis):

• Acute uncomplicated lower urinary tract infection in women
• 3 gm (one packet) dissolved in water — taken one time

For Multi-Drug Resistant UTI (Complicated):

• 3 gm (one packet) dissolved in water, every 72 hours for 3 doses
• Recommended as first-line empiric therapy for acute uncomplicated bacterial cystitis

Additional Indications:

• Recurrent UTI in women with MDRO infections
• UTI management during pregnancy — well tolerated and safe for use
• Complicated UTI requiring single-dose compliance-friendly therapy

Patient and Clinician Benefits

• Single-dose convenience — eliminates multi-day course compliance failure
• Well tolerated with minimal systemic side effects
• Safe for use during pregnancy
• Enhanced patient compliance due to single-administration format
• Reduces risk of antibiotic resistance development from prolonged courses
• Recommended as first-line by major clinical guidelines for uncomplicated cystitis

Directions for Use

• Open the packet and pour all powder into half a cup of water
• Do not use hot water
• Stir until the powder is dissolved and drink immediately

The UTI Burden in India

UTIs are among the most significant health concerns in India — affecting millions of women annually and frequently increasing the risk of complications when inadequately treated or when treatment is abandoned due to multi-day course non-compliance. Antibiotic treatment for acute episodes has many drawbacks, and alternative therapies are actively sought to reduce antimicrobial resistance. Apiphos addresses this challenge directly — with a single-dose solution backed by FDA approval and robust clinical evidence.

Composition